Table II.

Initiation Data

	Total (n= 79)*	Romiplostim (n= 51)	Eltrombopag (n= 36)	p value+
Reason for starting a TPO-RA
Bleeding symptoms	29 (37%)	23 (45%)	9 (25%)	0.07
Failed other therapies	23 (29%)	14 (27%)	11 (31%)	0.81
Resume activities	8 (10%)	2 (4%)	7 (19%)	0.02
Improve health-related quality of life	6 (8%)	4 (8%)	3 (8%)	0.31
Provider concern about low platelet count	5 (6%)	4 (8%)	1 (3%)	0.24
Avoid splenectomy	1 (1%)	1 (2%)	1 (3%)	0.49
Parental request	2 (3%)	0	2 (6%)	0.17
Prior to surgical procedure	4 (5%)	3 (6%)	1 (3%)	0.34

^*includes 8 patients who received both romiplostim and eltrombopag,

⁺comparing romiplostim to eltrombopag